Prostate Cancer ICD-10 Code: Complete Guide for Providers

Prostate cancer is among the common cancers that men receive a diagnosis for. For healthcare providers taking care of prostate cancer means more than diagnosing and treating. Accurate medical coding for prostate cancer is vital, for recording patient care proving necessity and lowering unnecessary insurance claim denials.

The main prostate cancer ICD‑10 code is C61, which stands for a tumor of the prostate.

However not every prostate encounter should use code C61. A patient who is only getting screening or who is receiving active prostate cancer treatment or who is coming back for a follow‑up after finishing prostate cancer treatment may need a different diagnosis code.

These differences are important. For example using a cancer code for a person who only has a history of prostate cancer can cause problems, between the medical record and the insurance claim.

This guide talks about the ICD-10-CM codes related to prostate cancer when to use those codes the CPT and HCPCS codes that go with them what needs to be written down and billing problems. It also looks at coding for cancer that has spread, checking for cancer and what to do after treatment.

What Is the ICD-10 Code for Prostate Cancer?

The ICD-10-CM code for prostate cancer is C61 – Malignant neoplasm of prostate.

This code is used when the patient has a documented, active malignant tumor originating in the prostate gland.

C61 may apply when a patient:

• Has a confirmed diagnosis of active prostate cancer.

• Is receiving treatment directed at the primary prostate malignancy.

• Is undergoing active surveillance for previously diagnosed prostate cancer.

• Has remaining active cancer following surgery or other treatment.

Confirmed diagnosis is essential. An elevated prostate-specific antigen level, digital rectal exam or suspicious imaging result does not alone prove prostate cancer.

Providers must write the diagnosis clearly of simply assigning C61 from a suspected malignancy.

Prostate Cancer ICD-10 Codes and Related Diagnoses

The correct code depends on the patients condition and the purpose of the encounter. The following table lists commonly used ICD-10-CM codes, for prostate cancer care for prostate cancer care.

These codes cannot be used interchangeably. The choice of code depends on the documentation the patient’s disease status and the specific coding guidelines for the encounter.

The FY 2027 ICD-10-CM code set is effective for all encounters occurring from October 1 2026, through September 30 2027.

When Should Providers Use C61 Instead of Z85.46?

One of the most important distinctions in prostate cancer coding is the difference between an active malignancy and a personal history of cancer.

C61: Active prostate cancer

C61 is appropriate when prostate cancer remains active or treatment is still directed at the primary malignancy.

Consider a patient diagnosed with localized prostate adenocarcinoma who undergoes a radical prostatectomy. Before surgery, C61 identifies the active cancer. If subsequent radiation is directed at the primary site following surgery, C61 may continue to apply while that treatment is ongoing.

C61 can also remain appropriate for patients undergoing active surveillance. Although these patients may not be receiving immediate surgery or radiation, their diagnosed cancer has not been eradicated.

Z85.46: Personal history of prostate cancer

Z85.46 is used when the original primary cancer has been removed or cured there is no sign that the cancer’s still present at that location and no ongoing treatment is being given for it.

For example a patient had a prostatectomy many years ago finished all treatments and now shows no signs of cancer. If the visit involves documenting the history of prostate cancer Z85.46 could be the code.

The official guidelines make it clear that a history code should not be used in place of a code, for a cancer if treatment is still being given for the original cancer.

ICD-10 Coding for Prostate Cancer Screening and Elevated PSA

Screening tests and diagnostic evaluations serve purposes. Screening tests and diagnostic evaluations require that the reason, for testing be reflected in the claim. The claim must clearly state the purpose of the testing.

Z12.5: Routine prostate cancer screening

Use Z12.5 when an eligible patient undergoes prostate cancer screening without an established diagnosis or a diagnostic concern requiring a different service classification.

Screening may involve PSA testing and, when clinically appropriate, other examinations.

For Medicare, the screening PSA service is commonly reported with HCPCS G0103. Screening coverage generally applies to eligible male beneficiaries aged 50 or older, subject to applicable frequency and coverage requirements.

R97.20: Elevated PSA

An elevated PSA level does not always mean a person has prostate cancer.

PSA levels can go up for reasons like having a larger prostate that is not cancerous having swelling or irritation in the prostate or having cancer. When the doctor writes that PSA is high but cancer has not been proven, using the code R97.20 could be correct.

For example a person has a PSA reading and is sent to a specialist to check more closely. If cancer has not been found yet using the code C61 would be soon.

R97.21: Rising PSA after prostate cancer treatment

R97.21 refers to a situation where the PSA level goes up after treatment for cancer in the prostate.

This code can be used when the PSA level increases, after surgery or other cancer treatments. The doctor hasn’t found a new cancer or a return of the old one.

If the cancer has definitely come back the code should show the confirmed cancer situation and where it’s instead of just using the high PSA result.

Understanding Prostate Cancer Stages and Their Coding Implications

Prostate cancer is commonly divided into four major stages. The stage helps clinicians assess how far the disease has progressed and select an appropriate treatment approach.

Cancer can affect lymph nodes or distant areas like the bones. C61 and other suitable codes, for cancers might be needed, depending on whether the disease is active and where it has spread.

Important: ICD-10-CM C61 stays the same because of the stage of prostate cancer. The stage, the Gleason score, the Grade Group, PSA. Whether the cancer has spread should still be recorded because they affect treatment and medical necessity.

The National Cancer Institute explains how to stage prostate cancer using clinical factors, including TNM classification, PSA level and Grade Group.

How to Code Metastatic Prostate Cancer

Prostate cancer can spread beyond its location. I find that bone and lymph nodes are among the sites where prostate cancer spreads.

When prostate cancer metastasis is confirmed I understand that providers may need to report both the malignancy and additional codes, for the secondary sites.

Common secondary malignancy codes

For example a patient who has primary prostate cancer and confirmed bone metastases may need the codes C61 and C79.51.

The first diagnosis that you write depends on why the patient is here. If the treatment is aimed at a secondary site, that secondary malignancy may be listed first.

Another important situation happens when the prostate cancer has been cleared but metastatic disease still exists. In those cases you can use the secondary malignancy code together with Z85.46 instead of automatically writing C61 again.

Medical records should clearly list the history of cancer the current sites of disease and where treatment is focused. This helps you tell the difference, between prostate cancer and a separate primary malignancy.

Relevant CPT and HCPCS Codes for Prostate Cancer

ICD-10-CM codes describe the patient’s diagnosis while CPT and HCPCS codes identify the services provided.

Prostate cancer care may involve PSA testing, imaging, biopsies, pathology examinations, surgical procedures and ongoing treatment. Each service must be supported by clinical documentation.

Common CPT codes used in prostate cancer care

These codes are examples. They do not include every prostate cancer procedure. Choosing the code depends on the actual service provided the technique used the documentation and the CPT instructions that apply.

For instance a prostate biopsy done through the route might need different coding compared to a transperineal biopsy. Likewise the choice of a PET imaging code depends on how much imaging’s done, the method used and the radiopharmaceutical involved.

Medicare pathology rules: CMS requires using HCPCS G0416 of CPT 88305 for the surgical pathology review of prostate needle biopsy samples according to its policy. The 2026 National Correct Coding Initiative manual states that one unit of G0416 should be billed for all prostate needle biopsy specimens from a patient.

Providers must check payer- rules any updates, to coding guidelines and the applicable National Correct Coding Initiative edits before submitting claims.

Prostate Cancer Screening: CPT and HCPCS Billing

Screening and diagnostic PSA testing are not necessarily billed the same way.

Medicare uses the following HCPCS codes for covered prostate cancer screening services.

A diagnostic PSA test, such as CPT 84153 might be the choice when testing is done because of a current condition, an unusual result or another clearly written reason for testing.

Medicare usually pays for annual screening PSA tests for male patients who are 50 years old or older. It is important to check the rules, for each patient and each service.

Physicians should not call a service a screening service just to get coverage. The diagnosis that is reported must clearly explain why the test was done.

ICD-10 Coding for Prostate Cancer Treatment

Prostate cancer treatment can include surgery, radiation therapy, systemic medication, active surveillance or a mix of these methods.

The right order, for diagnosis coding depends on what happens during the patient’s visit.

Radical prostatectomy

For a patient having surgery to take out prostate cancer C61 is usually the correct main or first diagnosis for the cancer.

The operation record needs to have the procedure done the reason for the surgery and any important results. If the treatment is a assisted radical prostatectomy the right codes, for that procedure should also be checked.

Radiation therapy

When an encounter is chiefly for the administration of external beam radiation therapy, Z51.0 – Encounter for antineoplastic radiation therapy is generally sequenced first, followed by the malignancy being treated.

For example:

• First-listed diagnosis: Z51.0

• Additional diagnosis: C61

An important exception applies when radioactive elements are inserted or implanted, like, in brachytherapy. According to the ICD-10-CM guidelines the correct cancer code should be listed first for that visit instead of Z51.0.

Chemotherapy and immunotherapy

For encounters chiefly involving the administration of qualifying antineoplastic treatments, the guidelines identify:

The underlying cancer is also reported.

Not every prostate cancer medication encounter qualifies for Z51.11 or Z51.12. Hormonal therapy androgen deprivation therapy and other drug treatments must be evaluated according to the service provided and applicable coding instructions.

Active surveillance

Patients with risk prostate cancer can choose regular PSA testing, clinical checks, MRI scans and repeated biopsies. This approach is used of immediate full treatment.

When prostate cancer remains present the patient is, under surveillance. In that case C61 continues to represent the diagnosis.

Active surveillance should not be confused with follow-up care after a malignancy has been completely treated.

The National Cancer Institute recognizes active surveillance as an important management approach for selected patients with localized prostate cancer.

Documentation Requirements for Accurate Prostate Cancer Coding

The quality of the clinical record has a direct impact on the accuracy of diagnosis coding and the ability to support billed services.

An effective prostate cancer record should clearly explain the patient’s current cancer status, reason for care, and treatment decisions.

Clinical documentation checklist

For instance, a provider may document a patient as having a history of prostate cancer while also indicating that additional radiation treatment is planned. That record may require clarification because treatment directed at the primary malignancy can affect whether C61 or Z85.46 is appropriate.

Clear documentation helps resolve these questions before claim submission.

Common Prostate Cancer Coding and Billing Mistakes

Even when the primary diagnosis is correct, claims may encounter problems because the supporting codes, documentation, or payer requirements do not match.

1. Reporting C61 without a confirmed diagnosis

An elevated PSA level or abnormal screening finding alone does not justify an active cancer diagnosis.

For outpatient encounters, providers should report the established findings or conditions rather than coding an uncertain cancer diagnosis as confirmed.

2. Using Z85.46 while cancer treatment remains active

A previous prostatectomy does not automatically mean the patient should receive a history code.

If additional treatment is still directed at the primary malignancy, the active cancer code may remain appropriate under the official coding guidelines.

3. Omitting metastatic disease

When a patient has confirmed bone or lymph node metastases, failing to report the relevant secondary malignancy codes may leave the claim inconsistent with the clinical record.

4. Incorrectly coding PSA testing

Screening PSA testing and diagnostic PSA testing have different indications and may follow different billing rules.

The claim should reflect the reason for testing rather than using a routine screening diagnosis for every PSA order.

5. Insufficient documentation for advanced imaging

MRI, PET imaging, and other diagnostic services may require evidence supporting medical necessity.

The documentation should explain the clinical purpose, such as staging, suspected recurrence, or assessment of disease progression, and satisfy the payer’s applicable policy.

6. Missing prior authorization

Certain imaging studies, procedures, and specialty treatments may require authorization.

Providers should confirm whether authorization is necessary before performing nonemergency services.

Common Claim Denial Codes in Prostate Cancer Billing

Prostate cancer claims can be denied for reasons unrelated to the patient’s diagnosis, including authorization, eligibility, missing information, or coding inconsistencies.

Understanding the Claim Adjustment Reason Code (CARC) helps providers identify the next step.

The adjustment group prefix, such as CO, identifies how the adjustment is categorized; it should not be treated as interchangeable with the numeric CARC.

CMS explains that electronic remittance advice may include a group code, CARC, and Remittance Advice Remark Code (RARC). The RARC often adds information needed to understand or resolve a specific adjustment.

How providers can reduce claim denials

A practical approach begins before the claim is submitted.

First, the patient’s insurance eligibility and applicable benefits should be verified. Next, the clinical record should support the diagnosis and procedures performed. Required authorizations, modifiers, units, and claim details should also be checked.

When a denial occurs, the provider should review the actual remittance codes and payer policy. A corrected claim is appropriate for some errors, while other situations may require additional records, reconsideration, or a formal appeal.

Not every denial is resolved by changing the diagnosis code. The correction must accurately reflect the service and documented condition.

How Medhasty Medical Billing Supports Prostate Cancer Claims

Prostate cancer claims often involve multiple stages of care, including diagnostic testing, pathology, specialized imaging, surgical services, radiation therapy, and follow-up visits. Each stage brings different coding and payer requirements.

Medhasty Medical Billing helps healthcare providers manage these complexities through medical billing, coding support, claim submission, denial management, and accounts receivable follow-up.

By reviewing diagnosis and procedure code relationships, verifying payer requirements, and addressing claim issues promptly, practices can reduce avoidable administrative delays and improve the consistency of their revenue cycle.

Accurate coding remains rooted in the provider’s clinical documentation. A structured billing process helps ensure that documented services are translated into claims that meet applicable reporting requirements.

Prostate Cancer ICD-10 Coding Updates for FY 2027

The FY 2027 ICD-10-CM code set became effective on October 1, 2026.

Healthcare providers should use the code set applicable to the date of service and review annual changes before updating clinical and billing workflows.

The FY 2027 official coding guidelines continue to distinguish between active malignancy, personal history of malignancy, encounters for treatment, and follow-up examinations.

These distinctions are particularly important when coding patients who have undergone prostatectomy, completed radiation, or developed metastatic disease after prior treatment.

Frequently Asked Questions About Prostate Cancer ICD-10 Codes

1. What is the ICD-10 code for prostate cancer?

The ICD-10-CM code for active malignant neoplasm of the prostate is C61. It is used when a provider has documented active primary prostate cancer.

2. What is the ICD-10 code for a history of prostate cancer?

Z85.46 identifies a personal history of malignant neoplasm of the prostate. It generally applies after the primary cancer has been eradicated, when no evidence of the malignancy remains at that site and no further treatment is directed at it.

3. What ICD-10 code is used for prostate cancer screening?

Z12.5 is the ICD-10-CM code for an encounter for screening for malignant neoplasm of the prostate. The procedure code depends on the screening service performed and the payer’s requirements.

4. What is the ICD-10 code for metastatic prostate cancer?

C61 identifies active primary prostate cancer, while additional codes describe confirmed metastatic sites. For example, C79.51 identifies secondary malignant neoplasm of bone. Code selection depends on the active disease and documented sites.

5. Can C61 be used after a prostatectomy?

Yes, in certain situations. If treatment continues to be directed at the primary cancer, C61 may remain appropriate. When the cancer has been eradicated and all treatment directed at that site is complete, Z85.46 may become appropriate.

6. Does elevated PSA mean the patient should be coded with C61?

No. Elevated PSA does not establish prostate cancer. R97.20 may be appropriate for a documented elevated PSA level without confirmed malignancy. R97.21 may apply when PSA rises after prostate cancer treatment.

Conclusion

Accurate prostate cancer coding begins with understanding the patient’s current condition and the reason for care.

C61 is the primary ICD-10-CM code for active prostate cancer, but related codes such as Z85.46, Z12.5, R97.20, and C79.51 are equally important in the appropriate clinical situations.

Providers should pay particular attention to the distinction between active cancer and historical disease, the documentation of metastatic sites, and diagnosis sequencing during cancer treatment.

Using current coding guidelines, maintaining complete records, and reviewing payer requirements can help reduce preventable denials and support timely claim processing.